- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Tinzaparin did not improve survival in patients with colorectal cancer: BMJ
![Tinzaparin did not improve survival in patients with colorectal cancer: BMJ Tinzaparin did not improve survival in patients with colorectal cancer: BMJ](https://medicaldialogues.in/h-upload/2020/01/16/750x450_123117-injection-3.jpg)
Canada: Extended duration of perioperative anticoagulation with tinzaparin did not impact the disease-free survival or overall survival in patients with colorectal cancer following surgery, says an article published in the British Medical Journal.
Tinzaparin, a low molecular weight heparin, has demonstrated antimetastatic properties in preclinical models by possibly preventing tumor cell invasion of the extracellular matrix, impeding immune-mediated destruction of tumor cells in the circulation, and preventing the neovascularization of micro-metastases due to an antiangiogenic effect.
Between October 25, 2011, and December 31, 2020, 12 hospitals in Quebec and Ontario, Canada, participated in this multicenter, open label, randomized controlled experiment. Participants 614 people (age 18) who had invasive adenocarcinoma of the colon or rectum that had been pathologically verified, showed no signs of metastatic illness, had hemoglobin concentrations below 8 g/dL, and were planned for surgical resection were eligible. When compared to in-patient postoperative thromboprophylaxis alone, extended duration thromboprophylaxis with daily subcutaneous tinzaparin at 4500 IU, starting at the decision to operate, lasts for 56 days. The main result was disease-free survival at three years, which was defined as survival without death, distant metastases, a second primary for the same cancer, a second primary for a different malignancy, or locoregional recurrence. Secondary results were five year overall survival, serious surgical bleeding problems, and venous thromboembolism. Intent-to-treat analysis was conducted on this population.
The key findings of this study were:
1. 235 (77%) of the 307 patients in the prolonged duration group and 243 (79%) of the 307 patients in the in-hospital thromboprophylaxis group experienced the main result.
2. Five patients (2%) in the prolonged period group and four patients (1%) in the in-hospital thromboprophylaxis group experienced postoperative venous thromboembolism (P=0.8).
3. One individual (1%) in the prolonged duration group and six (2%), who received in-hospital thromboprophylaxis, experienced major surgery-related bleeding in the first postoperative week (P=0.1).
4. There was no difference in overall survival at five years between the 272 (89%) extended duration patients and the 280 (91%) in-hospital thromboprophylaxis patients.
Reference:
Auer, R. C., Ott, M., Karanicolas, P., Brackstone, M. R., Ashamalla, S., Weaver, J., Tagalakis, V., Boutros, M., Stotland, P., Marulanda, A. C., Moloo, H., Asmis, T., … Carrier, M. (2022). Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial. In BMJ (p. e071375). BMJ. https://doi.org/10.1136/bmj-2022-071375
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751